Clinical trial: Semaglutide lowers cardiovascular events in adults who are overweight or obese but do not have diabetes by 20%.

Published Date: 15 Nov 2023

According to a doctor at Cleveland Clinic, semaglutide decreased cardiovascular events in adults with established cardiovascular disease who were overweight or obese by 20 percent. These findings came from a multi-center, international clinical trial.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot